<DOC>
	<DOCNO>NCT01641952</DOCNO>
	<brief_summary>This observational , prospective , multicenter study evaluate efficacy safety MabThera/Rituxan participant active rheumatoid arthritis inadequate response intolerance one anti-TNF therapy . Participants receive MabThera/Rituxan accord current standard line summary product characteristic dose 1000 milligram ( mg ) intravenously Days 1 15 follow 20 week .</brief_summary>
	<brief_title>An Observational Study MabThera/Rituxan ( Rituximab ) Patients With Rheumatoid Arthritis Inadequate Response Intolerance One Anti-Tumor Necrosis Factor ( Anti-TNF ) Agent</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Adult participant , &gt; /= 18 year age Participants rheumatoid arthritis , eligible treatment MabThera/Rituxan accordance summary product characteristic ( SPC ) Inadequate response single TNF inhibitor define change disease activity score28 erythrocyte sedimentation rate ( DAS28ESR ) &lt; 1.2 DAS28ESR &gt; 3.5 5 month first course antiTNF therapy Participants clinical biological evaluation perform within 12 week prior enrollment may include More one previous antiTNF therapy Any biological therapy apart one antiTNF therapy Hypersensitivity rituximab excipients murine protein Active severe infection Participants severely immunocompromised state Severe heart failure [ New York Heart Association ( NYHA ) Class IV ] severe , uncontrolled cardiac disease Women childbearing potential willing use contraception Pregnant breastfeed woman Participation another trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>